{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:37:36Z","timestamp":1774363056486,"version":"3.50.1"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T00:00:00Z","timestamp":1390435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0085905","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T23:35:37Z","timestamp":1390520137000},"page":"e85905","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":47,"title":["The Incidence of Liver Injury in Uyghur Patients Treated for TB in Xinjiang Uyghur Autonomous Region, China, and Its Association with Hepatic Enzyme Polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1"],"prefix":"10.1371","volume":"9","author":[{"given":"Yang","family":"Xiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atikaimu","family":"Wubuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiumei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,1,23]]},"reference":[{"key":"ref1","unstructured":"World Health Organization (2011) Global tuberculosis control: WHO report2011. Geneva: World Health Organization. 1\u201311."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1164\/ajrccm.164.7.2109052","article-title":"Hepatotoxicity from rifampin plus pyrazinamide:lessons for policymakers and messages for care providers","volume":"164","author":"WJ Burman","year":"2001","journal-title":"Am J Respir Crit CareMed"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"D Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"JJ Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","first-page":"167","article-title":"Antituberculous drug-induced liver injury: current perspective","volume":"32","author":"H Devarbhavi","year":"2011","journal-title":"Trop Gastroenterol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"WW Yew","year":"2006","journal-title":"Respirology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJM199510263331706","article-title":"Drug-induced hepatotoxicity","volume":"333","author":"WM Lee","year":"1995","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","article-title":"Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis","volume":"84","author":"JR Mitchell","year":"1976","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S0090-9556(25)07422-7","article-title":"Effects of hydrazine,phenelzine, and hydralazine treatment on rat hepatic and renal drug-metabolizing enzyme expression","volume":"24","author":"M Runge-Morris","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0378-4274(99)00230-1","article-title":"Glutathione S-transferase: genetics and role in toxicology","volume":"112\u2013113","author":"RC Strange","year":"2000","journal-title":"Toxicol Lett"},{"key":"ref11","first-page":"1530","article-title":"Genetical and geographic studies on isoniazid inactivation","volume":"Science10","author":"S Sunahara","year":"1961"},{"key":"ref12","first-page":"70","article-title":"Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites","volume":"Ther18","author":"JR Mitchell","year":"1975","journal-title":"Clin Pharmacol"},{"key":"ref13","first-page":"295","article-title":"Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype","volume":"Hepatology6","author":"T Yamamoto","year":"1986"},{"key":"ref14","first-page":"132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"Thorax51","author":"JN Pande","year":"1996"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.3.1.1","article-title":"Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury","volume":"3","author":"S Huang Y","year":"2007","journal-title":"Expert Opini.Drug Metab.Toxicol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"YS Huang","year":"2002","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/147323001003800324","article-title":"Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients","volume":"38","author":"T Wang","year":"2010","journal-title":"J Int Med Res"},{"key":"ref18","first-page":"622","article-title":"NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis druginduced hepatitis","volume":"14","author":"SW Lee","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1665-2681(19)31446-2","article-title":"NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population","volume":"11","author":"XZ Lv","year":"2012","journal-title":"Ann Hepatol"},{"key":"ref20","first-page":"99","article-title":"[The relationship between polymorphisms of N-acetyltransferase 2 genes and anti-tuberculosis drug induced hepatic-injury]","volume":"28","author":"M Guo","year":"2010","journal-title":"Zhonghua Chuan Ran Bing Za Zhi"},{"key":"ref21","first-page":"444","article-title":"[Association between polymorphism of N-acetyltransferase 2 gene and development of antituberculosis drug-induced liver injury].ZhongHua Sheng Wu Yi Xue Gong Cheng Za","volume":"Zhi17","author":"DS Huang","year":"2011"},{"key":"ref22","first-page":"256","article-title":"Slow Nacetyltransferase 2 genotype affects the incidence of isoniazid and rifampicininduced hepatotoxicity","volume":"4","author":"M Ohno","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"CytochromeP450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"YS Huang","year":"2003","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1440-1681.2012.05713.x","article-title":"NAT 2 and CYP2E1polymorphisms associated with antituberculosis drug-induced hepatotoxicity inChinese patients","volume":"39","author":"HR An","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref25","first-page":"551","article-title":"Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis druginduced hepatotoxicity in Korean patients with pulmonary tuberculosis.Tuberculosis (Edinb)","volume":"87","author":"HJ Cho","year":"2007"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2217\/pgs.09.100","article-title":"Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis","volume":"10","author":"SH Kim","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2217\/pgs.09.66","article-title":"Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population","volume":"10","author":"S Yamada","year":"2009","journal-title":"Pharmacogenomics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","article-title":"Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis","volume":"26","author":"PD Bose","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","first-page":"716","article-title":"Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and theoccurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients.Mem Inst Oswaldo Cruz","volume":"106","author":"RL Teixeira","year":"2011"},{"key":"ref30","first-page":"803","article-title":"Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients","volume":"25","author":"T Sotsuka","year":"2011","journal-title":"In Vivo"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2710.2012.01334.x","article-title":"CYP2E1, GSTM1and GSTT1 genetic polymorphisms and susceptibility to antituberculosis druginduced hepatotoxicity: a nested case-control study","volume":"37","author":"SW Tang","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"ref32","first-page":"864","article-title":"[Relationship between genetic polymorphisms of GSTM1, GSTT1 and the susceptibility to antituberculosis drug-induced liver injury]","volume":"36","author":"DL Zhu","year":"2011","journal-title":"Zhongguo Kang Sheng Su Za Zhi"},{"key":"ref33","first-page":"465","article-title":"GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs.J Clin Pharm Ther","volume":"35","author":"S Chatterjee","year":"2010"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tube.2009.12.001","article-title":"GSTT1 and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans","volume":"90","author":"SH Kim","year":"2010","journal-title":"Tuberculosis (Edinb)"},{"key":"ref35","first-page":"266","article-title":"[The effect of GST M1and GST T1 gene mutations on anti-tuberculous drug induced hepatic injury].Zhonghua Jie He He Hu Xi Za Zhi","volume":"32","author":"M Guo","year":"2009"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1478-3231.2008.01700.x","article-title":"Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population","volume":"28","author":"V Leiro","year":"2008","journal-title":"Liver Int"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2007.02.009","article-title":"Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: quinine oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury","volume":"47","author":"YS Huang","year":"2007","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1440-1746.2001.02585.x","article-title":"Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione Stransferase M1 \u2018null\u2019 mutation","volume":"16","author":"B Roy","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders. Report of aninternational consensus meeting","volume":"11","author":"C Benichou","year":"1990","journal-title":"J Hepatol"},{"key":"ref40","first-page":"335","article-title":"Liver injury during anti-tuberculosis treatment: an 11-year study.Tuber.Lung","volume":"Dis77","author":"M Dossing","year":"1996"},{"issue":"Ann.Pharmacother38","key":"ref41","first-page":"1074","article-title":"Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk","volume":"factors","author":"R Shakya","year":"2004"},{"key":"ref42","first-page":"883","article-title":"Polymorphism of the Nacetyltransferase2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"Hepatology35","author":"YS Huang","year":"2002"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","article-title":"CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis","volume":"62","author":"N Vuilleumier","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00228-008-0484-8","article-title":"Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil","volume":"64","author":"LG Possuelo","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"ref45","first-page":"467","article-title":"[The association between NAT2 polymorphism and anti-tuberculosis drug-induced hepatitis]","volume":"zhi18","author":"YM Wu","year":"2010","journal-title":"Zhonghua gan zang bing za"},{"key":"ref46","first-page":"3531","article-title":"Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2nucleic acid substitutions","volume":"Res55","author":"DW Hein","year":"1995","journal-title":"Cancer"},{"key":"ref47","first-page":"36","article-title":"[The associations of polymorphism of N-acetyltransferase 2 gene is associated with antitubercuiosis drug-induced hepatotoxicity in tuberculosis patients]","volume":"Med45","author":"HR An","year":"2011","journal-title":"Chin J Prev"},{"key":"ref48","first-page":"45","article-title":"A comprehensive review of genetic association studies.Genet","volume":"Med4","author":"JN Hirschhorn","year":"2002"},{"key":"ref49","first-page":"239","article-title":"[The study on the susceptible gene of isoniazid and rifampicin-induced hepatotoxicity of pulmonary tuberculosis patients]","volume":"Sch25","author":"JH Wang","year":"2004","journal-title":"Acad J PLA Postgrad Med"},{"key":"ref50","first-page":"503","article-title":"Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese population.Pharmacogenetics","volume":"7","author":"HG Xie","year":"1997"},{"key":"ref51","first-page":"748","article-title":"[Study of the relationship between polymorphisms of cytochrome P4502E1 and antituberculosis drug-induced hepatic injury].Zhonghua Chuan Ran Bing Za","volume":"Zhi28","author":"Y Chen","year":"2010"},{"key":"ref52","first-page":"585","article-title":"[Association of P450\u20132E1 and GSTM1 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity]","volume":"32","author":"T Wang","year":"2009","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"ref53","first-page":"784","article-title":"Predisposition of antituberculosis drug induced hepatotoxicity by cytochromeP450 2E1 genotype and haplotype in pediatric patients","volume":"Hepatol21","author":"B Roy","year":"2006","journal-title":"J Gastroenterol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1042\/bj2740409","article-title":"Theta, a new class of glutathione transferases purified from rat and man","volume":"274","author":"J Meyer D","year":"1991","journal-title":"Biochem J"},{"issue":"Hepatology52","key":"ref55","first-page":"748","article-title":"Pharmacogenetics of Drug-induced Liver","volume":"Injury","author":"S Russmann","year":"2010"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/14622416.9.3.311","article-title":"Pharmacogenomics of anti-TB drugsrelated hepatotoxicity","volume":"9","author":"PD Roy","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref57","first-page":"192","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.J Gastroenterol Hepatol","volume":"23","author":"A Tostmann","year":"2008"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bdd.557","article-title":"The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats","volume":"28","author":"HJ De Rosa","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pharmthera.2007.09.004","article-title":"Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic,pharmacoepigenetic and clinical aspects","volume":"116","author":"M Ingelman-Sundberg","year":"2007","journal-title":"Pharmacol Ther"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1432-1033.1996.0476z.x","article-title":"Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period","volume":"238","author":"I Vieira","year":"1996","journal-title":"Eur J Biochem"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.bcp.2009.11.015","article-title":"Human CYP2E1 is regulated by miR-378","volume":"79","author":"T Mohri","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"ref62","first-page":"916","article-title":"Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.Am J Respir Crit Care","volume":"Med166","author":"SK Sharma","year":"2002"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0085905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T17:00:15Z","timestamp":1746118815000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0085905"}},"subtitle":[],"editor":[{"given":"Mark Patrick","family":"Nicol","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,23]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0085905","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,23]]}}}